Haohai Biological (6826) reported, in its preliminary annual results for the year ended December 31, 2025, that revenue declined 8.33% year-on-year to 2.47 billion. Net profit attributable to owners decreased by 40.30%, to about 251.01 million, while net profit after deducting non-recurring items declined 57.67%. These declines were primarily attributed to national volume-based procurement of ophthalmic intraocular lens (IOL) products, broadening market competition, and an overall drop in domestic cataract surgeries.

Total assets amounted to around 6.76 billion, down 5.12% from the beginning of the reporting period, while equity attributable to owners stood at about 5.45 billion, a 2.33% decrease. According to the announcement, goodwill and certain intangible assets related to two subsidiaries in the IOL business were impaired, reflecting the intensified competition and anticipated price adjustments in the upcoming round of national procurement.

The final financial results remain subject to audit and are expected to be reflected in the 2025 annual report.